Krebs Biochemicals & Industries Limited (KREBSBIO.NS) NSE
Currency In INR
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
191
First IPO Date
October 27, 2016
| Name | Title | Pay | Year Born |
| Manish Kumar Jain | MD, Chief Executive Officer & Director | 30,000 | 1976 |
| Rakesh Kalbate | Company Secretary & Compliance Officer | 0 | N/A |
| Ritesh Jain | Chief Financial Officer | 0 | N/A |
Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing biotechnological processes applicable to the medical, agricultural, and industrial sectors. Its current portfolio includes compounds like androstenedione, lovastatin, and simvastatin, which serve as steroid intermediates and anti-cholesterol agents. Furthermore, Krebs Biochemicals is actively developing new products such as amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, targeting diverse therapeutic applications including anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough relief. The firm also extends its expertise by offering contract manufacturing services to large pharmaceutical and multinational corporations.